BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 11584766)

  • 1. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
    Tucker T; Yeats J
    S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
    [No Abstract]   [Full Text] [Related]  

  • 2. Access to essential medications for HIV/AIDS in South Africa.
    Andrews S
    S Afr Med J; 2001 May; 91(5):384-7. PubMed ID: 11455797
    [No Abstract]   [Full Text] [Related]  

  • 3. Generic drugs battle moves from South Africa to Kenya.
    Siringi S
    Lancet; 2001 May; 357(9268):1600. PubMed ID: 11377665
    [No Abstract]   [Full Text] [Related]  

  • 4. Affordable drug access for developing countries.
    Highleyman L
    BETA; 2001; 14(2):12-25. PubMed ID: 11785481
    [No Abstract]   [Full Text] [Related]  

  • 5. Working together to provide generics for health.
    Beck EJ; Reiss P
    Antivir Ther; 2014; 19 Suppl 3():1. PubMed ID: 25310234
    [No Abstract]   [Full Text] [Related]  

  • 6. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
    Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
    AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
    [No Abstract]   [Full Text] [Related]  

  • 7. Cheap HIV drugs for developing countries.
    Int J Epidemiol; 2001 Jun; 30(3):651-2. PubMed ID: 11460820
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a role for generic antiretroviral drugs in the United States?
    Wormser GP; Lappas T
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):897-9. PubMed ID: 24918192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. World Trade Organization still threatens supply of affordable AIDS drugs.
    Hagmann M
    Bull World Health Organ; 2002; 80(9):762-3. PubMed ID: 12378300
    [No Abstract]   [Full Text] [Related]  

  • 10. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
    't Hoen E
    Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
    [No Abstract]   [Full Text] [Related]  

  • 11. Physicians say generic AIDS drugs don't threaten R&D.
    AIDS Policy Law; 2002 Mar; 17(6):4. PubMed ID: 12004757
    [No Abstract]   [Full Text] [Related]  

  • 12. [Access to treatment of HIV/AIDS in the South: the challenges of sustainability].
    Kazatchkine M; Moatti JP
    Med Sci (Paris); 2008 Dec; 24(12):1007-8. PubMed ID: 19116101
    [No Abstract]   [Full Text] [Related]  

  • 13. Access to treatment for HIV/AIDS: a human rights issue in the developing world.
    Joni J
    Conn J Int Law; 2002; 17(2):273-80. PubMed ID: 12688296
    [No Abstract]   [Full Text] [Related]  

  • 14. Access to HIV drugs: are we changing the two world paradigm?
    Lazzarini Z
    Conn J Int Law; 2002; 17(2):281-96. PubMed ID: 12688297
    [No Abstract]   [Full Text] [Related]  

  • 15. HIV/AIDS: Latin America & Caribbean. Brazil: ten years after.
    Cohen J
    Science; 2006 Jul; 313(5786):484-7. PubMed ID: 16873654
    [No Abstract]   [Full Text] [Related]  

  • 16. Crunch time for funding of universal access to antiretroviral treatment for people with HIV infection.
    Maher D; von Schoen-Angerer T; Cohn J
    Int J Clin Pract; 2011 Aug; 65(8):824-7. PubMed ID: 21762306
    [No Abstract]   [Full Text] [Related]  

  • 17. The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report.
    Herrmann S; Wardrop J; John M; Gaudieri S; Lucas M; Mallal S; Nolan D
    Sex Health; 2012 Nov; 9(5):407-13. PubMed ID: 22950904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. India: New patent law may restrict access to HIV/AIDS treatments.
    Cruess G
    HIV AIDS Policy Law Rev; 2005 Aug; 10(2):28-30. PubMed ID: 16365971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production of antiretroviral drugs in middle- and low-income countries.
    Pinheiro Edos S; BrĂ¼ning K; Macedo MF; Siani AC
    Antivir Ther; 2014; 19 Suppl 3():49-55. PubMed ID: 25310755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.